Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone

H. Logan Brooks, Sergio Caballero, Charles K. Newell, Robert L. Steinmetz, Debbie Watson, Mark S. Segal, Jeffrey K. Harrison, Edward W. Scott, Maria B. Grant

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Background: Diffuse macular edema (DME) and/or aberrant neovascularization (NV) can cause vision loss in diabetic retinopathy (DR) and may be modulated by growth factors and chemokines. The chemokine stromal-derived factor 1 (SDF-1) is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of NV, and the key inducer of vascular permeability associated with DME. Circulating endothelial cell precursors migrating in response to SDF-1 participate in NV. Objective: To investigate the relationship between SDF-1 and (VEGF) in vitreous of patients with varying degrees of DR and DME before and after intraocular injection of triamcinolone acetonide, used to treat refractory DME. Methods: In this prospective study, 36 patients were included and observed for 6 months. Vitreous VEGF and SDF-1 levels were measured by enzyme-linked immunosorbent assay in samples obtained immediately before and 1 month after injection of triamcinolone. Results: Both VEGF and SDF-1 were significantly higher (P2=0.88). Conclusions: Triamcinolone administration resulted in dramatic reductions of VEGF and SDF-1 to nearly undetectable levels, eliminated DME, and caused regression of active NV. Our results support a role for SDF-1 and VEGF in the pathogenesis of the adverse visual consequences of DR and suggest that the elimination of DME with regression and/or initiation of fibrosis of NV after triamcinolone injection may be due to the suppression of VEGF and SDF-1.

Original languageEnglish (US)
Pages (from-to)1801-1807
Number of pages7
JournalArchives of Ophthalmology
Volume122
Issue number12
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Intraocular Injections
Triamcinolone
Macular Edema
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Chemokines
Triamcinolone Acetonide
Injections
Capillary Permeability
Intercellular Signaling Peptides and Proteins
Fibrosis
Endothelial Cells
Enzyme-Linked Immunosorbent Assay
Prospective Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. / Brooks, H. Logan; Caballero, Sergio; Newell, Charles K.; Steinmetz, Robert L.; Watson, Debbie; Segal, Mark S.; Harrison, Jeffrey K.; Scott, Edward W.; Grant, Maria B.

In: Archives of Ophthalmology, Vol. 122, No. 12, 12.2004, p. 1801-1807.

Research output: Contribution to journalArticle

Brooks, H. Logan ; Caballero, Sergio ; Newell, Charles K. ; Steinmetz, Robert L. ; Watson, Debbie ; Segal, Mark S. ; Harrison, Jeffrey K. ; Scott, Edward W. ; Grant, Maria B. / Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. In: Archives of Ophthalmology. 2004 ; Vol. 122, No. 12. pp. 1801-1807.
@article{8f4577b8418f44bfb7fad642e2af60fe,
title = "Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone",
abstract = "Background: Diffuse macular edema (DME) and/or aberrant neovascularization (NV) can cause vision loss in diabetic retinopathy (DR) and may be modulated by growth factors and chemokines. The chemokine stromal-derived factor 1 (SDF-1) is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of NV, and the key inducer of vascular permeability associated with DME. Circulating endothelial cell precursors migrating in response to SDF-1 participate in NV. Objective: To investigate the relationship between SDF-1 and (VEGF) in vitreous of patients with varying degrees of DR and DME before and after intraocular injection of triamcinolone acetonide, used to treat refractory DME. Methods: In this prospective study, 36 patients were included and observed for 6 months. Vitreous VEGF and SDF-1 levels were measured by enzyme-linked immunosorbent assay in samples obtained immediately before and 1 month after injection of triamcinolone. Results: Both VEGF and SDF-1 were significantly higher (P2=0.88). Conclusions: Triamcinolone administration resulted in dramatic reductions of VEGF and SDF-1 to nearly undetectable levels, eliminated DME, and caused regression of active NV. Our results support a role for SDF-1 and VEGF in the pathogenesis of the adverse visual consequences of DR and suggest that the elimination of DME with regression and/or initiation of fibrosis of NV after triamcinolone injection may be due to the suppression of VEGF and SDF-1.",
author = "Brooks, {H. Logan} and Sergio Caballero and Newell, {Charles K.} and Steinmetz, {Robert L.} and Debbie Watson and Segal, {Mark S.} and Harrison, {Jeffrey K.} and Scott, {Edward W.} and Grant, {Maria B.}",
year = "2004",
month = "12",
doi = "10.1001/archopht.122.12.1801",
language = "English (US)",
volume = "122",
pages = "1801--1807",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone

AU - Brooks, H. Logan

AU - Caballero, Sergio

AU - Newell, Charles K.

AU - Steinmetz, Robert L.

AU - Watson, Debbie

AU - Segal, Mark S.

AU - Harrison, Jeffrey K.

AU - Scott, Edward W.

AU - Grant, Maria B.

PY - 2004/12

Y1 - 2004/12

N2 - Background: Diffuse macular edema (DME) and/or aberrant neovascularization (NV) can cause vision loss in diabetic retinopathy (DR) and may be modulated by growth factors and chemokines. The chemokine stromal-derived factor 1 (SDF-1) is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of NV, and the key inducer of vascular permeability associated with DME. Circulating endothelial cell precursors migrating in response to SDF-1 participate in NV. Objective: To investigate the relationship between SDF-1 and (VEGF) in vitreous of patients with varying degrees of DR and DME before and after intraocular injection of triamcinolone acetonide, used to treat refractory DME. Methods: In this prospective study, 36 patients were included and observed for 6 months. Vitreous VEGF and SDF-1 levels were measured by enzyme-linked immunosorbent assay in samples obtained immediately before and 1 month after injection of triamcinolone. Results: Both VEGF and SDF-1 were significantly higher (P2=0.88). Conclusions: Triamcinolone administration resulted in dramatic reductions of VEGF and SDF-1 to nearly undetectable levels, eliminated DME, and caused regression of active NV. Our results support a role for SDF-1 and VEGF in the pathogenesis of the adverse visual consequences of DR and suggest that the elimination of DME with regression and/or initiation of fibrosis of NV after triamcinolone injection may be due to the suppression of VEGF and SDF-1.

AB - Background: Diffuse macular edema (DME) and/or aberrant neovascularization (NV) can cause vision loss in diabetic retinopathy (DR) and may be modulated by growth factors and chemokines. The chemokine stromal-derived factor 1 (SDF-1) is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of NV, and the key inducer of vascular permeability associated with DME. Circulating endothelial cell precursors migrating in response to SDF-1 participate in NV. Objective: To investigate the relationship between SDF-1 and (VEGF) in vitreous of patients with varying degrees of DR and DME before and after intraocular injection of triamcinolone acetonide, used to treat refractory DME. Methods: In this prospective study, 36 patients were included and observed for 6 months. Vitreous VEGF and SDF-1 levels were measured by enzyme-linked immunosorbent assay in samples obtained immediately before and 1 month after injection of triamcinolone. Results: Both VEGF and SDF-1 were significantly higher (P2=0.88). Conclusions: Triamcinolone administration resulted in dramatic reductions of VEGF and SDF-1 to nearly undetectable levels, eliminated DME, and caused regression of active NV. Our results support a role for SDF-1 and VEGF in the pathogenesis of the adverse visual consequences of DR and suggest that the elimination of DME with regression and/or initiation of fibrosis of NV after triamcinolone injection may be due to the suppression of VEGF and SDF-1.

UR - http://www.scopus.com/inward/record.url?scp=10044242430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044242430&partnerID=8YFLogxK

U2 - 10.1001/archopht.122.12.1801

DO - 10.1001/archopht.122.12.1801

M3 - Article

C2 - 15596583

AN - SCOPUS:10044242430

VL - 122

SP - 1801

EP - 1807

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -